CARsgen Therapeutics Holdings (HKSE:02171) Cash-to-Debt : 21.71 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is CARsgen Therapeutics Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. CARsgen Therapeutics Holdings's cash to debt ratio for the quarter that ended in Dec. 2023 was 21.71.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, CARsgen Therapeutics Holdings could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for CARsgen Therapeutics Holdings's Cash-to-Debt or its related term are showing as below:

HKSE:02171' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.14 Med: 10.4 Max: 21.71
Current: 21.71

During the past 5 years, CARsgen Therapeutics Holdings's highest Cash to Debt Ratio was 21.71. The lowest was 1.14. And the median was 10.40.

HKSE:02171's Cash-to-Debt is ranked better than
65.2% of 1523 companies
in the Biotechnology industry
Industry Median: 6.46 vs HKSE:02171: 21.71

CARsgen Therapeutics Holdings Cash-to-Debt Historical Data

The historical data trend for CARsgen Therapeutics Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

CARsgen Therapeutics Holdings Cash-to-Debt Chart

CARsgen Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

1.14

10.40

8.90

18.99

21.71

CARsgen Therapeutics Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial				8.90	7.97	18.99	19.57	21.71

Competitive Comparison of CARsgen Therapeutics Holdings's Cash-to-Debt

For the Biotechnology subindustry, CARsgen Therapeutics Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARsgen Therapeutics Holdings's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARsgen Therapeutics Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where CARsgen Therapeutics Holdings's Cash-to-Debt falls into.

CARsgen Therapeutics Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

CARsgen Therapeutics Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2023.22	/	(16.135	+	77.076)
	=	21.71

CARsgen Therapeutics Holdings's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2023.22	/	(16.135	+	77.076)
	=	21.71

CARsgen Therapeutics Holdings (HKSE:02171) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

CARsgen Therapeutics Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of CARsgen Therapeutics Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CARsgen Therapeutics Holdings (HKSE:02171) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARsgen Therapeutics Holdings Ltd (HKSE:02171) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

CRTHF:USA

Address

No. 388 Yindu Road, Building 12, CMC Preparation Center, Xuhui District, Shanghai, CHN

Website

https://www.carsgen.com

CARsgen Therapeutics Holdings Ltd is a global clinical-stage biopharmaceutical company discovering, researching and developing cell therapies in the People's Republic of China and the United States of America.

Executives

Guo Bingsen	2401 A concert party to an agreement to buy shares
Guo Huaqing	2101 Beneficial owner
Li Zonghai	2401 A concert party to an agreement to buy shares
Wang Huamao	2401 A concert party to an agreement to buy shares
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Gic Private Limited	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Yang Zhi	2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd	2201 Interest of corporation controlled by you
Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Zhejiang Jolly Healthcare Investment Management Limited	2201 Interest of corporation controlled by you
Applied Biomaterial Ltd.	2201 Interest of corporation controlled by you
Zhejiang Jolly Pharmaceutical Co., Ltd.	2201 Interest of corporation controlled by you
Zhejiang Zuoli Innovation Medical Investment Management Co., Ltd.	2101 Beneficial owner

CARsgen Therapeutics Holdings (HKSE:02171) Headlines

No Headlines